Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTIMMUNE Extension in Friedreich's Ataxia
NCT02797080Phase 3Completed
- Sponsor
- Amgen
- Start
- Jun 2016
- Primary completion
- Mar 2017
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of interferon gamma-1b in Friedreich's ataxia (FA), sponsored by Amgen. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs. Started Jun 2016; status: completed.
02
Drugs
interferon gamma-1b
03
Conditions
Friedreich's ataxia (FA)
Beyond the preview
Go deeper on NCT02797080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02797080.